Literature DB >> 28205352

Successful treatment of C1q nephropathy with CD19 targeted Rituximab therapy.

Raja Ramachandran1, Joyita Bharati1, Vivekanand Jha2.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2017        PMID： 28205352     DOI： 10.1111/nep.12757

Source DB:  PubMed          Journal:  Nephrology (Carlton)        ISSN： 1320-5358            Impact factor:   2.506


× No keyword cloud information.
  2 in total

1.  C1q nephropathy in adults is a form of focal segmental glomerulosclerosis in terms of clinical characteristics.

Authors:  Kipyo Kim; Hyung-Eun Son; Ji-Young Ryu; Hajeong Lee; Seung Hyeok Han; Dong-Ryeol Ryu; Jin Ho Paik; Sejoong Kim; Ki Young Na; Dong-Wan Chae; Ho Jun Chin; Se Won Oh
Journal:  PLoS One       Date:  2019-04-19       Impact factor: 3.240

2.  Case Report: Complete Remission of C1q Nephropathy Treated With a Single Low-Dose Rituximab, a Reality or Coincidence?

Authors:  Rui Ma; Dengyan Wu; Zhiqin He; Qian Chang; Yonghong Yang
Journal:  Front Pediatr       Date:  2021-02-04       Impact factor: 3.418
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.